1,500
Views
19
CrossRef citations to date
0
Altmetric
Research Paper

Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer

, , , , , , , , , , & show all
Pages 245-251 | Received 15 Dec 2016, Accepted 09 Feb 2017, Published online: 27 Mar 2017

References

  • Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66:115-32; PMID:26808342; http://dx.doi.org/10.3322/caac.21338
  • Klangsin S, Suntharasaj T, Suwanrath C, et al. Comparison of the five sonographic morphology scoring systems for the diagnosis of malignant ovarian tumors. Gynecol Obstet Invest 2012; 76:248-53; PMID:24192793; http://dx.doi.org/10.1159/000355563
  • Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, Vasiliou V. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 2011; 5:283-303; PMID:7779080; http://dx.doi.org/10.1186/1479-7364-5-4-283
  • Stewart MJ, Malek K, Xiao Q, Dipple KM, Crabb DW. The novel aldehyde dehydrogenase gene, ALDH5, encodes an active aldehyde dehydrogenase enzyme. Biochem Biophys Res Commun 1955; 211:144-51; PMID:7779080; http://dx.doi.org/10.1006/bbrc.1995.1789
  • Kaur H, Mao S, Li Q, Sameni M, Krawetz SA, Sloane BF, Mattingly RR. RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target. PLoS ONE 2012; 7:e50249; PMID:23236365; http://dx.doi.org/10.1371/journal.pone.0050249
  • Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K. Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 2010; 70(23):9765-76; PMID:21118967; http://dx.doi.org/10.1158/0008-5472.CAN-10-0130
  • Chambliss KL, Zhang YA, Rossier E, Vollmer B, Gibson KM. Enzymatic and immunologic identification of succinic semialdehyde dehydrogenase in rat and human neural and nonneural tissues. J Neurochem 1995; 65:851-5; PMID:7616245; http://dx.doi.org/10.1046/j.1471-4159.1995.65020851.x
  • EL-Hadaad HA. Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer. Ann Diagn Pathol 2014; 18:58-62; PMID:24342665; http://dx.doi.org/10.1016/j.anndiagpath.2013.11.004
  • Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012; 19:197-208; PMID:22277193; http://dx.doi.org/10.1530/ERC-11-0329
  • Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013; 73:5016-28; PMID:23824740; http://dx.doi.org/10.1158/0008-5472.CAN-13-0023
  • Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221:49-56; PMID:20229506; http://dx.doi.org/10.1002/path.2696
  • The Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian cancer. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/10.1038/nature10166
  • Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Könsgen D, Dietel M, Fiehn O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006; 66:10795-804; PMID:17108116; http://dx.doi.org/10.1158/0008-5472.CAN-06-0755
  • Nicholson-Guthrie CS, Guthrie GD, Sutton GP, Baenziger JC. Urine GABA levels in ovarian cancer patients: Elevated GABA in malignancy. Cancer Lett 2001; 162:27-30; PMID:11121859; http://dx.doi.org/10.1016/S0304-3835(00)00620-0
  • Kamieniak MM, Rico D, Milne RL, Muñoz-Repeto I, Ibáñez K, Grillo MA, Domingo S, Borrego S, Cazorla A, García-Bueno JM. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. Mol Oncol 2015; 9:422-36; PMID:25454820; http://dx.doi.org/10.1016/j.molonc.2014.09.010
  • Gayarre J, Kamieniak MM, Cazorla-Jimenez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, et al. The NER related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. J Gynecol Oncol 2015; 12:12; PMID:26463438; http://dx.doi.org/10.3802/jgo.2016.27.e7
  • Giselly Encinas1, Simone Maistro2, Maria Aparecida Azevedo Koike Folgueira, et al. Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis. Rev Assoc Med Bras 2015; 61(5):474-83; PMID:26603012; http://dx.doi.org/10.1590/1806-9282.61.05.474

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.